PPARGC1A and metabolic dysfunction-associated steatotic liver disease: This upregulates PGC-1α and inhibits lipid accumulation in the liver through the BHMT/FTO/m6A/PGC-1α pathway to alleviate NAFLD (94) (Figure 5A).